PRISM MediaWire

Incannex’s Psilocybin Targets Anxiety with Positive Topline Results

New York, N.Y., February 29, 2024 - PRISM MediaWire - PRISM MarketView - Leading cannabinoid and psychedelic medicine biotechnology company, Incannex Healthcare (Nasdaq: IXHL), has achieved positive topline results in its Phase 2 clinical trial of psilocybin in generali...

29 February 2024

PRISM MarketView

PRISM MarketView Highlights Work of Emerging Companies on Rare Disease Day

NEW YORK, N.Y., February 29, 2024 - PRISM MediaWire - PRISM MarketView, a leading provider of unbiased market insight and company news, recognizes the remarkable contributions of companies developing treatments for the 10,000 rare diseases affecting more than 30 million ...

29 February 2024

PRISM MarketView

Investors Are Having a Cow. Plant-Based Beyond Meat (BYND) Exceeds Q4 Revenue Estimates, Promises to Steeply Cut Costs.

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - PRISM Zombie Index Leader Beyond Meat, Inc. (BYND), is seeing a big gain today as its trading close to 45% higher on its recent earnings release. However, outside of exceeding the Street’s Q4 revenu...

28 February 2024

PRISM MarketView

MindMed Closes Out 2023 with Positive Phase 2b Results for Generalized Anxiety Treatment

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - Mind Medicine (MindMed) Inc. (Nasdaq: MNMD) has announced its financial results for the year ended December 31, 2023, closing out a “highly productive” year with positive Phase 2b results for MM120 ...

28 February 2024

PRISM MarketView

PRISM Rare Disease Spotlight: Capricor Therapeutics Advances Treatment for Duchenne Muscular Dystrophy

New York, N.Y., February 28, 2024 - PRISM MediaWire - PRISM MarketView - Rare disease company, Capricor Therapeutics (Nasdaq: CAPR), has been granted an in-person Type-B meeting with the FDA to discuss chemistry, manufacturing and controls (CMC) plans for commercial laun...

28 February 2024

PRISM MarketView

PRISM Rare Disease Spotlight: Voyager Therapeutics Selects Development Candidate for Friedreich’s Ataxia, Triggers $5M Milestone Payment

New York, N.Y., February 27, 2024 - PRISM MediaWire - PRISM MarketView - Voyager Therapeutics (Nasdaq: VYGR) has selected a lead development candidate in its Friedreich’s Ataxia (FA) program. The company expects the program to advance into first-in-human clinical trials ...

27 February 2024

PRISM MarketView

SunPower Secures Over $300M in Financing to Fuel Expansion of Residential Solar and Storage Solutions

New York, February 23, 2024 - PRISM MarketView - PRISM MediaWire - SunPower Corp. (Nasdaq: SPWR), an emerging player in the residential solar technology and energy services sector, has successfully secured over $300 million in project financing commitments. This funding,...

23 February 2024

PRISM MarketView

PRISM Med Device Index Tech Company Vapotherm, Inc. (VAPO) Announces Fourth Quarter Earnings

New York, February 23, 2024 - PRISM MarketView - PRISM MediaWire - PRISM Emerging Med Device Index tech company Vapotherm (VAPO) specializes in the development and commercialization of innovative respiratory support devices. The company is known for its high-flow therapy...

23 February 2024

PRISM MarketView

Incannex’s CBD Chewing Gum Offers Hope for Smokers Looking to Quit

New York, February 23, 2024 - PRISM MarketView - PRISM MediaWire - Leading cannabinoid and psychedelic medicine company, Incannex Healthcare (Nasdaq: IXHL), has completed a pre-IND (Investigational New Drug) meeting with the FDA regarding the development of CannQuit-N fo...

23 February 2024

PRISM MarketView

All Charged Up: PRISM Emerging EV Index Ideal Power (IPWR) Up Over 75% in Past Five Days

New York, February 22, 2024 - PRISM MarketView - PRISM MediaWire - The PRISM Emerging EV tech company Ideal Power Inc. (IPWR) develops and commercializes power conversion solutions for various industries, including energy storage, renewable energy, and electric vehicles....

22 February 2024